Home > Insider Trading > Filing (0001079974-13-000320)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1389870	Omni Bio Pharmaceutical Inc.	OMBP	Biological Products, (No Disgnostic Substances) (2836)	208097969

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1377756	Boco Investments Llc	262 E. Mountain Ave. Fort Collins CO 80524		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2010-12-02	725,000	$0.25	3,134,000	No	4	C	Direct
Common Stock	Acquisiton	2013-04-08	2,000,000	$0.25	5,134,000	No	4	P	Direct
Common Stock	Acquisiton	2013-05-30	2,000,000	$0.25	7,134,000	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	P	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrant (Right to Buy)	Disposition	2010-12-02	725,000	$0.00	725,000	$0.25
Common Stock	Convertible Note	Acquisiton	2012-10-31	2,400,000	$600,000.00	2,400,000	$0.25
Common Stock	Warrant (Right to Buy)	Acquisiton	2012-10-31	600,000	$0.00	600,000	$1.50

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2009-03-31	2013-12-31	No	4	X	Direct
2,400,000	2012-10-31	2015-10-31	No	4	P	Direct
3,000,000	2012-10-31	2017-10-31	No	4	P	Direct

Footnotes

The Warrant, as with others held by Reporting Person , becomes exercisable to the extent that such exercise or conversion would not result in aggregate Beneficial Ownership of greater than 19.99%. The number shown in #9 reflects Beneficial Ownership as determined in accordance with Exchange Act Section 13(d).
The Reporting Person purchased a Convertible Promissory Note in the principal amount of $600,000. The Note bears interest at an annual rate of 10% and may be paid in cash and/or shares of the Company's common stock at the initial rate of $1.00 per share ("Conversion Rate"). The Conversion Rate is subject to adjustment based on subsequent Company financings and, at present, equals $0.25 per share of the Company's Common Stock.
In conjunction with Convertible Promissory Note referenced in Footnote 2, the Reporting Person received a Warrant to purchase 600,000 shares of the Company's common stock at an exercise price of $1.50 per share. The number of shares that be purchased under the Warrant may change due to anti-dilution provisions.